Contact
searchSearch
HMP Global
Login

Melanoma Resource Center

News
‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma
02/21/2024
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that...
02/21/2024
Oncology
From Oncology
News
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
02/20/2024
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an...
02/20/2024
Oncology
From Oncology
News
Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma
02/15/2024
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective...
02/15/2024
Oncology
From Oncology
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
Retrospective Study Shows Variations in BRAF Test Results in Turnaround Time Among Patients With Melanoma
04/28/2022
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma,...
04/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost of Ipilimumab vs High-Dose Interferon for Melanoma
11/11/2021
True or False: Although, compared to high-dose interferon, adjuvant ipilimumab improves survival and decreases toxicity in patients with resected, high-risk melanoma, it is not considered cost-effective.
True or False: Although, compared to high-dose interferon, adjuvant ipilimumab improves survival and decreases toxicity in patients with resected, high-risk melanoma, it is not considered cost-effective.
True or False: Although,...
11/11/2021
Journal of Clinical Pathways
Quiz
Quiz: Ipilimumab Among Patients With Metastatic Melanoma
10/29/2021
True or False: Real-world evidence suggests ipilimumab provides real option value, averaging 3.9 months of additional survival for patients with metastatic melanoma.
True or False: Real-world evidence suggests ipilimumab provides real option value, averaging 3.9 months of additional survival for patients with metastatic melanoma.
True or False: Real-world...
10/29/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of Ipilimumab vs High-Dose Interferon for High-Risk Melanoma
10/26/2021
Study findings revealed that adjuvant ipilimumab may not be a cost-effective treatment option compared to high-dose interferon in patients with resected, high-risk melanoma.
Study findings revealed that adjuvant ipilimumab may not be a cost-effective treatment option compared to high-dose interferon in patients with resected, high-risk melanoma.
Study findings revealed that...
10/26/2021
Journal of Clinical Pathways
News
Real-World Evidence for Option Value of Ipilimumab in Metastatic Melanoma
10/21/2021
Study findings provide real-world evidence of measurable real option value of ipilimumab for patients with metastatic melanoma.
Study findings provide real-world evidence of measurable real option value of ipilimumab for patients with metastatic melanoma.
Study findings provide...
10/21/2021
Journal of Clinical Pathways
Quiz
Quiz: Dermoscopic Structures and Patterns in Melanoma Detection
10/12/2021
True or False: There is diagnostic importance in dermoscopic structures and patterns associated with melanoma detection.
True or False: There is diagnostic importance in dermoscopic structures and patterns associated with melanoma detection.
True or False: There is...
10/12/2021
Journal of Clinical Pathways

Newsfeed

News
‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma
02/21/2024
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that...
02/21/2024
Oncology
News
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
02/20/2024
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an...
02/20/2024
Oncology
News
Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma
02/15/2024
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective...
02/15/2024
Oncology
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
Retrospective Study Shows Variations in BRAF Test Results in Turnaround Time Among Patients With Melanoma
04/28/2022
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma,...
04/28/2022
Journal of Clinical Pathways
News
Cost-Effectiveness of Ipilimumab vs High-Dose Interferon for High-Risk Melanoma
10/26/2021
Study findings revealed that adjuvant ipilimumab may not be a cost-effective treatment option compared to high-dose interferon in patients with resected, high-risk melanoma.
Study findings revealed that adjuvant ipilimumab may not be a cost-effective treatment option compared to high-dose interferon in patients with resected, high-risk melanoma.
Study findings revealed that...
10/26/2021
Journal of Clinical Pathways
News
Real-World Evidence for Option Value of Ipilimumab in Metastatic Melanoma
10/21/2021
Study findings provide real-world evidence of measurable real option value of ipilimumab for patients with metastatic melanoma.
Study findings provide real-world evidence of measurable real option value of ipilimumab for patients with metastatic melanoma.
Study findings provide...
10/21/2021
Journal of Clinical Pathways
News
Dermoscopic Structures and Patterns Important for Accurately Detecting Melanoma
09/15/2021
Findings from a systematic review and meta-analysis support the diagnostic importance of dermoscopic structures associated with melanoma detection and highlight the importance of the overall pattern.
Findings from a systematic review and meta-analysis support the diagnostic importance of dermoscopic structures associated with melanoma detection and highlight the importance of the overall pattern.
Findings from a systematic...
09/15/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of Adjuvant Therapies for BRAF-Mutant Melanoma
08/27/2021
Pembrolizumab is cost-effective for the treatment of BRAF-mutant stage III melanoma, but dabrafenib-trametinib is not, according to study findings.
Pembrolizumab is cost-effective for the treatment of BRAF-mutant stage III melanoma, but dabrafenib-trametinib is not, according to study findings.
Pembrolizumab is cost-effective...
08/27/2021
Journal of Clinical Pathways
News
Cost-Effectiveness of Adjuvant Therapy Among Medicare Patients With BRAF-Mutant Melanoma
08/05/2021
While dabrafenib–trametinib may offer incremental QALYs in patients with BRAF-mutant stage III melanoma, it is not considered a cost-effective regimen, according to study findings.
While dabrafenib–trametinib may offer incremental QALYs in patients with BRAF-mutant stage III melanoma, it is not considered a cost-effective regimen, according to study findings.
While dabrafenib–trametinib may...
08/05/2021
Journal of Clinical Pathways
News
Enhancing Survival in Endometrial Cancer: Impact of Immunotherapy and Chemotherapy Combination Therapy
11/13/2024
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with chemotherapy in the treatment of advanced endometrial cancer, particularly in cases of mismatch repair deficiency, has shown promising results in improving progression-free and overall survival outcomes according...
Combining immunotherapy with...
11/13/2024
Journal of Clinical Pathways
News
Under 50% of Oncology Practices Offer Survivorship Clinics
11/12/2024
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice groups offer a general survivorship clinic for cancer survivors, according to a study published online in JNCI Cancer Spectrum.
Just 41% of oncology practice...
11/12/2024
Journal of Clinical Pathways
News
Experts Reach Consensus on Myelofibrosis Management, Offering New Hope for Patients
11/08/2024
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international consensus program has provided vital clinical recommendations to enhance the treatment landscape for myelofibrosis (MF).
A comprehensive international...
11/08/2024
Journal of Clinical Pathways
News
Advancing Personalized Treatment in Endometrial Cancer With the HECTOR Deep Learning Model
11/06/2024
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published in Nature, endometrial cancer (EC) cases are on the rise, and 10% to 20% of patients with EC experience distant recurrence. In this study, in researchers aimed to predict distant recurrence of EC to improve...
According to a study published...
11/06/2024
Journal of Clinical Pathways
News
Influence of Socioeconomic and Demographic Factors on Myelofibrosis Outcomes
10/30/2024
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic disparities may improve survival for patients with myelofibrosis, according to a study published in Annals of Hematology.
Addressing socioeconomic...
10/30/2024
Journal of Clinical Pathways
News
Hypertension and Endometrial Cancer Risk: A Systematic Review and Meta-Analysis
10/25/2024
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and meta-analysis found a significant association between hypertension and an increased risk of endometrial cancer.
A systematic review and...
10/25/2024
Journal of Clinical Pathways
News
Harnessing the Potential of Abemaciclib in Recurrent Endometrial Cancer Treatment
10/25/2024
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor used in breast cancer treatment, shows promise in targeting novel mechanisms in endometrial cancer for potential therapeutic benefits in cases of recurrence, particularly in estrogen receptor-positive patients.
Abemaciclib, a CDK4/6 inhibitor...
10/25/2024
Journal of Clinical Pathways
News
Pembrolizumab Plus Adjuvant Chemotherapy for Newly Diagnosed High-Risk dMMR Endometrial Cancer
10/21/2024
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with adjuvant carboplatin-paclitaxel significantly improves disease-free survival in patients with high-risk mismatch repair-deficient endometrial cancer, according to a study published in the Journal of Clinical...
Pembrolizumab combined with...
10/21/2024
Journal of Clinical Pathways
News
False Negatives More Prevalent in Endometrial Cancer Screening for Black Women
10/17/2024
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA Oncology found that Black women are more likely to receive false negative results from transvaginal ultrasounds for endometrial cancer compared to White women, highlighting the need for improved diagnostic methods...
A study published in JAMA...
10/17/2024
Journal of Clinical Pathways
News
Efficacy of Momelotinib in Managing Anemia in Myelofibrosis: Results from the SIMPLIFY-2 Trial
10/16/2024
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in Therapy shows that momelotinib significantly improves anemia and related symptoms in patients with myelofibrosis, particularly those previously treated with ruxolitinib.
A study published in Advances in...
10/16/2024
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Cost of Ipilimumab vs High-Dose Interferon for Melanoma
11/11/2021
True or False: Although, compared to high-dose interferon, adjuvant ipilimumab improves survival and decreases toxicity in patients with resected, high-risk melanoma, it is not considered cost-effective.
True or False: Although, compared to high-dose interferon, adjuvant ipilimumab improves survival and decreases toxicity in patients with resected, high-risk melanoma, it is not considered cost-effective.
True or False: Although,...
11/11/2021
Journal of Clinical Pathways
Quiz
Quiz: Ipilimumab Among Patients With Metastatic Melanoma
10/29/2021
True or False: Real-world evidence suggests ipilimumab provides real option value, averaging 3.9 months of additional survival for patients with metastatic melanoma.
True or False: Real-world evidence suggests ipilimumab provides real option value, averaging 3.9 months of additional survival for patients with metastatic melanoma.
True or False: Real-world...
10/29/2021
Journal of Clinical Pathways
Quiz
Quiz: Dermoscopic Structures and Patterns in Melanoma Detection
10/12/2021
True or False: There is diagnostic importance in dermoscopic structures and patterns associated with melanoma detection.
True or False: There is diagnostic importance in dermoscopic structures and patterns associated with melanoma detection.
True or False: There is...
10/12/2021
Journal of Clinical Pathways
Quiz
Quiz: Pembrolizumab for the Treatment of BRAF-Mutant Stage III Melanoma
09/07/2021
True or False: For the treatment of BRAF-mutant stage III melanoma, pembrolizumab is most cost-effective at a conventional willingness-to-pay threshold.
True or False: For the treatment of BRAF-mutant stage III melanoma, pembrolizumab is most cost-effective at a conventional willingness-to-pay threshold.
True or False: For the treatment...
09/07/2021
Journal of Clinical Pathways
Quiz
Quiz: Dabrafenib–Trametinib for Treating Melanoma
08/23/2021
True or False: Dabrafenib–trametinib offers incremental quality-adjusted life years in patients with BRAF-mutant stage III melanoma, but it is not considered cost-effective.
True or False: Dabrafenib–trametinib offers incremental quality-adjusted life years in patients with BRAF-mutant stage III melanoma, but it is not considered cost-effective.
True or False:...
08/23/2021
Journal of Clinical Pathways
Quiz
Quiz: First-Year Costs Among Patients With Melanoma
08/18/2021
08/18/2021
Journal of Clinical Pathways
Quiz
Quiz: Ipilimumab for the Treatment of Metastatic Melanoma
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Quiz
Quiz: Adverse Event Costs Among Patients With Metastatic Melanoma
07/20/2021
True or False: Costs associated with adverse events among patients with metastatic melanoma are small, encompassing only 3% of total costs.
True or False: Costs associated with adverse events among patients with metastatic melanoma are small, encompassing only 3% of total costs.
True or False: Costs associated...
07/20/2021
Journal of Clinical Pathways
Quiz
Quiz: Immune Checkpoint Inhibitors (ICIs) in Cutaneous Metastatic Melanoma
03/10/2021
03/10/2021
Journal of Clinical Pathways
Quiz
Quiz: Medicare Fee-for-Service Pricing Impact on Skin Cancer Procedures
01/05/2021
01/05/2021
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of Margetuximab vs Trastuzumab for Breast Cancer
06/30/2022
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a willingness-to-pay threshold of $100,000 per quality-adjusted life year, margetuximab plus chemotherapy is cost-effective compared to trastuzumab plus chemotherapy for patients with ERBB2–positive, advanced breast...
True or False: Under a...
06/30/2022
Journal of Clinical Pathways
Quiz
Quiz: Real-World Treatment Patterns in Mantle Cell Lymphoma
06/28/2022
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and rituximab was the most used frontline regimen for the treatment of MCL, while BTK inhibitors were the most used agents in later lines of therapy.
True or False: Bendamustine and...
06/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Cost-Effectiveness of First-Line Treatments for Chronic Lymphocytic Leukemia
06/27/2022
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with venetoclax-plus-obinutuzumab, chemoimmunotherapies are associated with less health benefits at higher cost among patients with CLL.
True or False: Compared with...
06/27/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicare Reimbursement in Head and Neck Surgical Oncology
05/25/2022
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most common head and neck surgical oncologic procedure codes considered as a group, U.S. Centers for Medicare & Medicaid Services reimbursement decreased from 2000 through 2020.
True or False: For the 37 most...
05/25/2022
Journal of Clinical Pathways
Quiz
Quiz: BTKi's Among Patients With Relapsed/Refractory MCL
05/10/2022
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients with relapsed/refractory mantle cell lymphoma, second-generation Bruton’s tyrosine kinase inhibitors (BTKIs) provide an additional progression-free survival benefit compared with ibrutinib
True or False: Among patients...
05/10/2022
Journal of Clinical Pathways
Quiz
Quiz: Biosimilar vs Referent Trastuzumab for ERBB2–Positive Breast Cancer
05/06/2022
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a biosimilar to trastuzumab, demonstrated equivalence to referent trastuzumab in achieving a total pathological complete response and in safety in ERBB2–positive, early breast cancer.
True or False: HD201, a...
05/06/2022
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Recent Stories

News
‘Second Adjuvant’ Therapy With a BRAF/MEK Inhibitor Delayed Recurrence, Increased Toxicity Among Patients With BRAF-Mutated Melanoma
02/21/2024
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that ‘second adjuvant’ therapy with a BRAF/MEK inhibitor improved recurrence-free survival at the cost of toxicity among patients with BRAF-mutated melanoma who experienced disease recurrence after treatment with an...
Study results demonstrated that...
02/21/2024
Oncology
News
FDA Grants Accelerated Approval to Lifileucel for Unresectable or Metastatic Melanoma
02/20/2024
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an accelerated approval to lifileucel for patients unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600-positive, a BRAF inhibitor with or without a MEK inhibitor.
The FDA has granted an...
02/20/2024
Oncology
News
Antibiotic Exposure Prior to First-Line Immune Checkpoint Blockade Negatively Impacted Survival Outcomes Among Patients With Melanoma
02/15/2024
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective cohort study found that antibiotic exposure within 60 days prior to initiation of immune checkpoint blockade was associated with worse PFS and OS among patients with treatment-naïve cutaneous or mucosal melanoma.
Results from a retrospective...
02/15/2024
Oncology
News
Tracking Cost of Care Discussions Between Physicians and Patients with NSCLC and Melanoma
10/30/2023
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and Michael T. Halpern, MD, PhD, MPH, examine the documentation of cost of care discussions between physicians and patients with non–small cell lung cancer and melanoma.
Robin Yabroff, PhD, MBA, and...
10/30/2023
Journal of Clinical Pathways
News
Retrospective Study Shows Variations in BRAF Test Results in Turnaround Time Among Patients With Melanoma
04/28/2022
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma, delays in testing for BRAF mutations affect the type of therapeutic intervention and delay initiation of treatment, according to a retrospective study that mapped BRAF testing timelines.
In adult patients with melanoma,...
04/28/2022
Journal of Clinical Pathways

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use